Achyut shareholders to swap into Zenith at 119-for-50 ratio
Nano-cap API trader merges into WHO-certified manufacturer. Combined group could streamline operations, but deal awaits NCLT and shareholder approval.
— 1 earlier story on Achyut Healthcare Ltd. →What's new
- Board approved merger of Achyut Healthcare into Zenith Healthcare at 119:50 swap ratio.
- Achyut holds ₹38.09 cr assets, ₹11.97 cr revenue; Zenith holds ₹10.99 cr assets, ₹10.94 cr revenue.
- Deal aims to combine API trading with WHO cGMP-certified manufacturing under one entity.
Why this matters
This isn't a typical merger of equals. Achyut trades at a P/E of 607 with a 1.8% ROE. Its latest quarter: ₹4 crore sales, zero profit. The swap gives shareholders a stake in a certified manufacturer with export capability, effectively swapping a high-PE trading stock for a manufacturing business. The combined entity must prove it can generate the profits that justify the structure.
What we're watching
- NCLT and shareholder approval timelines.
- Whether BSE issues a no-objection letter smoothly.
- Post-merger financials: can the combined entity improve on Achyut's thin margins?
The full read
Achyut Healthcare, a nano-cap with a market cap of ₹192 crore, is merging into group entity Zenith Healthcare. The board approved a swap ratio of 119 Zenith shares for every 50 Achyut shares — 2.38 shares of a WHO cGMP-certified manufacturer for each share of what was largely an API trader. Achyut's financials are thin: ₹38.09 crore in assets, ₹11.97 crore in revenue. Zenith is slightly smaller at ₹10.99 crore and ₹10.94 crore. Combined, they would have assets of roughly ₹49 crore. The deal's logic is structural: replace a trading business with a manufacturing one. Yet Achyut's latest quarter tells a cautionary tale: sales of just ₹4 crore, net profit zero. The stock trades at a P/E of 607 and an ROE of 1.8%. This merger could change the business entirely or it could be a reshuffling of paper. Pending NCLT and shareholder approvals, the outcome hinges on whether the combined entity can produce sustainable profits.
Questions answered
- What is the exact swap ratio?
- Achyut shareholders receive 119 equity shares of Zenith for every 50 shares of Achyut held, or 2.38 Zenith shares per Achyut share.
- Why merge Achyut into Zenith?
- The board cites streamlining group structure and combining capabilities: Achyut trades APIs, Zenith manufactures formulations with WHO cGMP certification and export reach.
- What approvals are still needed?
- The scheme requires NCLT approval, shareholder nods from both companies, and a no-objection letter from BSE.
- What are the financials of the two companies?
- Achyut reported total assets of ₹38.09 crore and revenue of ₹11.97 crore in FY26. Zenith had assets of ₹10.99 crore and revenue of ₹10.94 crore.
- How does this affect minority shareholders?
- Minority holders swap a high-PE, low-ROE stock for shares in a manufacturing company. The investment thesis shifts from trading to production, but execution risk remains until all approvals are in place.
Achyut Healthcare Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ACHYUT →- 14 Jul 2026 · 9:19 PM IST Achyut shareholders to swap into Zenith at 119-for-50 ratio
- 48d ago Achyut's revenue jumped 280%. Its profit fell.